2 months Biogen Stock Down on Regulatory Update in the EU for Alzheimer’s Drug Zacks
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai’s Leqembi in the EU for early AD.
X